Preview

Rational Pharmacotherapy in Cardiology

Advanced search

THE NEWS FROM RECENT CONGRESS OF AMERICAN COLLEGE OF CARDIOLOGY (NEW ORLEANS, APRIL 2-5, 2011)

https://doi.org/10.20996/1819-6446-2011-7-3-391-393

Full Text:

About the Authors

S. Yu. Martsevich

Russian Federation


N. P. Kutishenko

Russian Federation


L. Y. Drozdova

Russian Federation


References

1. Ogawa H., Kim-Mitsuyama S., Jinnouchi T. et al. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Hypertens Res 2009;32(7):575-80.

2. Matsushita K., Muramatsu T., Kondo T. et al; NAGOYA HEART Study Group. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. J Cardiol 2010;56(1):111-7.

3. Strauss M.H., Hall A.S. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2010;31(2):261-2.

4. Park K.W., Yoon J.H., Kim J.S. et al. Efficacy of Xience/promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) trial: study design and rationale of a Korean multicenter prospective randomized trial. Am Heart J. 2009 May;157(5):811-817.

5. Trial watch. DAPT study. Harv Heart Lett 2010;20(5):7.

6. Cohen A.T., Spiro T.E., Büller H.R. et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011 Feb 27 [Epub ahead of print].

7. Durand-Zaleski I., Bertrand M. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. Pharmacoeconomics 2004;22 Suppl 4:19-27.

8. Maron D.J., Boden W.E., Weintraub W.S. et al. Is Optimal Medical Therapy as Used in the COURAGE Trial Feasible for Widespread Use? Curr Treat Options Cardiovasc Med 2011;13(1):16-25.

9. George J.C., Varghese V., Dangas G., Popma J.J. Transcatheter aortic valve implantation: lessons from the PARTNER (Placement of Aortic Transcatheter Valves) trial. JACC Cardiovasc Interv 2011;4(1): 132-3.


For citation:


Martsevich S.Yu., Kutishenko N.P., Drozdova L.Y. THE NEWS FROM RECENT CONGRESS OF AMERICAN COLLEGE OF CARDIOLOGY (NEW ORLEANS, APRIL 2-5, 2011). Rational Pharmacotherapy in Cardiology. 2011;7(3):391-393. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-3-391-393

Views: 263


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)